Suzhou Ribo Life Science Co., Ltd. (Ribo) and Ribocure Pharmaceuticals AB(Ribocure) have announced a strategic partnership with Pheiron to leverage its cutting-edge AI platform, PheironGPS, in Ribo’s discovery and development of RNA-based therapeutics. This collaboration aims to enhance Ribo’s target discovery capacity in cardiometabolic diseases by integrating advanced human evidence generated through Pheiron’s AI technology.

PheironGPS systematically integrates human multi-omic data at scale to pinpoint biological mechanisms and drive actionable insights on targets and patient populations. This collaboration will establish a strong scientific connection between therapeutic targets and disease causality, offering unprecedented guidance for the clinical development of Ribo’s RNA-based therapeutics.

Dr. Li Ming Gan, Co-CEO and Global Head of R&D at Ribo, remarked: “We can now access multi-omic information from both general and specific patient populations. We are delighted to collaborate with the highly skilled scientists at Pheiron. Their proprietary AI algorithms, combined with our experienced scientists and drug developers, will help unravel complex patho-physiological networks. This collaboration will increase our success rate in discovering novel biology and disease pathways linked to unmet medical needs in the cardiometabolic area”

Thore Buergel, CEO of Pheiron said: “Human population-scale datasets are transforming how we understand and treat disease. PheironGPS is bringing human evidence to the forefront of decision-making, delivering clarity on disease mechanisms and patient populations that can significantly raise the probability of success in therapeutical development. We are delighted to collaborate with Ribo and shape the next generation of RNA therapeutics with evidence from large human populations”.